Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures -- Ignore unavailable to you. Want to Upgrade?

To: ACAN who wrote (4228)	3/15/2008 9:39:11 PM
From: ~digs	Respond to of 7944

[DVAX] DYNAVAX TECHNOLOG > 5.95 +0.24 (+4.20%) Open > 5.74 Volume > 156862 Dynavax Technologies Corporation discovers, develops, and focuses on commercializing Toll-like Receptor 9 (TLR9) agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using proprietary approaches that alter immune system responses in specific ways. Its TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. The company's product candidates include: HEPLISAV, a hepatitis B vaccine in Phase 3 partnered with Merck & Co., Inc.; TOLAMBA, a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Dynavax Technologies also has products in preclinical studies, which include vaccines for influenza, anthrax, and autoimmune disorders, as well as hepatitis C therapeutic program. Its preclinical asthma and COPD program is partnered with AstraZeneca AB. The company receives program support from the National Institutes of Health for its preclinical work on a vaccine for influenza; from Symphony Dynamo, Inc. for its colorectal cancer trials and preclinical hepatitis C therapeutic program; and from Deerfield for its allergy programs. Dynavax Technologies was founded in 1996 and is based in Berkeley, California.